PDF
XLS
DOC
DOC
View Report
Transparency Report
Prescription Drug Net Pricing
As Net Prices Decline
Our R&D Investments
What We Believe
Citations
Fast Facts
2022 Executive Summary
2022 at a Glance
$39 Billion: Breaking It Down
Rebates, Discounts and Fees Provided to Intermediaries
The 340B Program
Additional Resources
More
Menu
View Report
Transparency Report
Prescription Drug Net Pricing
As Net Prices Decline
Our R&D Investments
What We Believe
Citations
Fast Facts
2022 Executive Summary
2022 at a Glance
$39 Billion: Breaking It Down
Rebates, Discounts and Fees Provided to Intermediaries
The 340B Program
Additional Resources
More
View Report
Transparency Report
Prescription Drug Net Pricing
As Net Prices Decline
Our R&D Investments
What We Believe
Citations
Fast Facts
2022 Executive Summary
2022 at a Glance
$39 Billion: Breaking It Down
Rebates, Discounts and Fees Provided to Intermediaries
The 340B Program
Additional Resources
More
Previous Reports and Additional Resources
The 2021 Janssen U.S. Transparency Report
Download
The 2021 Janssen U.S. Transparency Report Executive Summary
Download
How Insurers Divert Co-Pay Support Meant
for Patients
Download
The 2020 Janssen U.S. Transparency Report
Download
The 2020 Janssen U.S. Transparency Report Executive Summary
Download
2019 Janssen U.S. Transparency Report
Janssen offers a more detailed look at the price reductions it offer payers and others in the healthcare system to support access to its medicines.
Download
2019 Janssen U.S. Transparency Report Executive Summary
Download
2018 Janssen U.S. Transparency Report
Download
2018 Janssen U.S. Transparency Report Executive Summary
Download
2017 Janssen U.S. Transparency Report
Download
2017 Janssen U.S. Transparency Report Executive Summary
Download
2016 Janssen U.S. Transparency Report
Download
2016 Janssen U.S. Transparency Report Executive Summary
Download
✕
Internet Explorer is not supported by this website.
For optimal browsing we recommend using
Chrome
,
Safari
, or
Firefox
.